Abstract: Method for preparing a 2,5-furandicarboxylic acid (“FDCA”) comprising: contacting a polypeptide comprising an amino acid sequence that has greater than 34% sequence identity with an amino acid sequence set out in SEQ ID NO:1 or SEQ ID NO:2 with furoic acid in the presence of carbon dioxide; wherein the polypeptide has carboxylase and decarboxylase activity and comprises (i) the amino acid corresponding to H297 or a functional substitution thereof and (ii) at least one of (a) the amino acid corresponding to R305 or a functional substitution thereof; and (b) the amino acid corresponding to R332 or a functional substitution thereof; wherein the position is numbered relative to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

Abstract: Embodiments of a transit ticket system are provided. The transit ticket system may include a mobile computing device configured to (i) download a mobile ticketing application from a ticket management server, the mobile ticketing application including a graphical data sheet, a ticket dictionary, and ticket strings, (ii) receive ticket rendering instructions from the ticket management server in response to completion of a ticket purchase process via the mobile computing device, and (iii) render for display an active ticket on the mobile computing device with data stored on the mobile computing device based on the ticket rendering instructions, the graphical data sheet, ticket dictionary, and ticket strings in response to an activation input command.

Abstract: The invention relates to a crystalline diethylamine tetrathiomolybdate salt (DEA-TTM). The invention also relates to methods for producing the crystalline DEA-TTM salt of the invention. The invention also relates to pharmaceutical compositions comprising the crystalline DEA-TTM salt of the invention. The invention also relates to the use of the crystalline DEA-TTM salt of the invention in the treatment of the human or animal body, in particular its use in treatment of a condition requiring reduced metabolism of an organ or the whole body of a patient, by administering to a patient in need thereof a therapeutically effective amount of the crystalline DEA-TTM salt.

Abstract: Tetrathiomolybdate is for use in therapy of a condition requiring reduced metabolism of an organ or whole body, e.g. myocardial infection, stroke or ischaemia-reperfusion injury.

Abstract: The invention relates to a crystalline diethylamine tetrathiomolybdate salt (DEA-TTM). The invention also relates to methods for producing the crystalline DEA-TTM salt of the invention. The invention also relates to pharmaceutical compositions comprising the crystalline DEA-TTM salt of the invention. The invention also relates to the use of the crystalline DEA-TTM salt of the invention in the treatment of the human or animal body, in particular its use in treatment of a condition requiring reduced metabolism of an organ or the whole body of a patient, by administering to a patient in need thereof a therapeutically effective amount of the crystalline DEA-TTM salt.

Abstract: Embodiments of a transit ticket system are provided. The transit ticket system may include a mobile computing device configured to (i) download a mobile ticketing application from a ticket management server, the mobile ticketing application including a graphical data sheet, a ticket dictionary, and ticket strings, (ii) receive ticket rendering instructions from the ticket management server in response to completion of a ticket purchase process via the mobile computing device, and (iii) render for display an active ticket on the mobile computing device with data stored on the mobile computing device based on the ticket rendering instructions, the graphical data sheet, ticket dictionary, and ticket strings in response to an activation input command.

Abstract: Embodiments of a transit ticket system are provided. The transit ticket system may include a mobile computing device configured to (i) download a mobile ticketing application from a ticket management server, the mobile ticketing application including a graphical data sheet, a ticket dictionary, and ticket strings, (ii) receive ticket rendering instructions from the ticket management server in response to completion of a ticket purchase process via the mobile computing device, and (iii) render for display an active ticket on the mobile computing device with data stored on the mobile computing device based on the ticket rendering instructions, the graphical data sheet, ticket dictionary, and ticket strings in response to an activation input command.

Abstract: Method for preparing a mono-unsaturated alkene comprising contacting an aliphatic mono-unsaturated carboxylic acid with an Fdc1 polypeptide comprising an amino acid sequence with at least 21% sequence identity to SEQ ID NO: 1 and a Pad1 polypeptide comprising an amino acid sequence with at least 17% sequence identity to SEQ ID NO: 2.

Abstract: Embodiments of a transit ticket system are provided. The transit ticket system may include a mobile computing device configured to (i) download a mobile ticketing application from a ticket management server, the mobile ticketing application including a graphical data sheet, a ticket dictionary, and ticket strings, (ii) receive ticket rendering instructions from the ticket management server in response to completion of a ticket purchase process via the mobile computing device, and (iii) render for display an active ticket on the mobile computing device with data stored on the mobile computing device based on the ticket rendering instructions, the graphical data sheet, ticket dictionary, and ticket strings in response to an activation input command.

Abstract: Method for preparing a mono-unsaturated alkene comprising contacting an aliphatic mono-unsaturated carboxylic acid with an Fdc1 polypeptide comprising an amino acid sequence with at least 21% sequence identity to SEQ ID NO: 1 and a Pad1 polypeptide comprising an amino acid sequence with at least 17% sequence identity to SEQ ID NO: 2.

Abstract: The present invention is a procedure that allows configuring a random access IEEE 802.11 wireless network, operating in infrastructure mode (all terminals communicate exclusively with an AP (Access Point)), in such a way that throughput is optimized when the network is saturated, satisfying traffic characteristics, in presence or absence of the hidden terminal phenomenon and the number of terminals that communicate with the AP. It may be applied to networks that run a specific application or to those that have devices that run different applications. This procedure can be translated into a program that is operated by a wireless network administrator for network configuration. This program may also be incorporated into the configuration program of an AP and devices conforming to these standards. This invention can be applied to devices that act as AP's, such as a bridge, switch or router and the configuration can be manual or automatic, static or dynamic.